You are here

Positive Phase III Results for Dulaglutide in Type 2 Diabetes

Non-inferiority to insulin glargine demonstrated in two studies (Apr. 16)

Positive results have been reported from two phase III trials of dulaglutide (Eli Lilly), an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist that is being studied as a once-weekly treatment for type 2 diabetes.

Primary efficacy endpoints of non-inferiority to insulin glargine, as measured by the reduction of hemoglobin A1c (HbA1c) levels at the 1.5 mg dose, were met in the AWARD-2 (Assessment of Weekly AdministRation of LY2189265 in Diabetes 2) trial and in the AWARD-4 trial. Superiority for HbA1c lowering was also examined. The 1.5 mg dose of dulaglutide demonstrated a statistically superior reduction in HbA1c from baseline compared with insulin glargine at 52 weeks in patients with type 2 diabetes receiving metformin and glimepiride (AWARD-2 trial). In addition, the 1.5 mg dose of dulaglutide in combination with insulin lispro demonstrated a statistically superior reduction in HbA1c from baseline compared with insulin glargine in combination with insulin lispro at 26 weeks (AWARD-4 trial).

AWARD-2 was a randomized, 78-week, open-label comparison of the effects of dulaglutide and insulin glargine on glycemic control in 807 patients with type 2 diabetes receiving metformin and glimepiride. The study’s primary objective was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, is non-inferior to insulin glargine in reducing HbA1c from baseline at 52 weeks.

AWARD-4 was a randomized, 52-week, open-label comparison of the effects of dulaglutide and insulin glargine, both administered in combination with insulin lispro, in 884 patients with type 2 diabetes. The study’s primary objective was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, in combination with insulin lispro, is non-inferior to insulin glargine in combination with insulin lispro in reducing HbA1c from baseline at 26 weeks.

In October 2012, the drug’s developer (Eli Lilly) announced positive top-line results from three other completed phase III AWARD trials: AWARD-1, AWARD-3, and AWARD-5. Primary efficacy endpoints, as measured by a reduction in HbA1c at the 1.5 mg dose, were met in all three studies.

Source: Eli Lilly; April 16, 2013.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions